Cabenuva vs Descovy
A side-by-side look at two hiv medications advertised on TV. Informational only — not medical advice.
| US Cabenuva | US Descovy | |
|---|---|---|
| Generic name | cabotegravir/rilpivirine | emtricitabine/tenofovir alafenamide |
| Drug class | Integrase Inhibitor / NNRTI (Long-Acting Injectable) | NRTI Combination |
| Treats | HIV-1 infection | HIV treatment and prevention (PrEP) |
| Category | HIV | HIV |
| Manufacturer | ViiV Healthcare | Gilead Sciences |
| Year approved | 2021 | 2016 |
| FDA warning | Moderate warnings | Black box warning |
| Est. TV ad spend | — | — |
| Common side effects | Injection site reactions, Fever, Fatigue, Headache | Diarrhea, Nausea, Headache, Worsening of hepatitis B if stopped (boxed warning) |
Frequently asked questions
Is Cabenuva or Descovy better?
Neither is universally "better." Cabenuva (cabotegravir/rilpivirine) and Descovy (emtricitabine/tenofovir alafenamide) are both used for hiv, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Cabenuva and Descovy?
Cabenuva is a Integrase Inhibitor / NNRTI (Long-Acting Injectable) made by ViiV Healthcare, while Descovy is a NRTI Combination made by Gilead Sciences. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Cabenuva has the larger estimated TV advertising budget of the two.